Global IgG4-Related Disease Market Insights, Epidemiology, and Market Forecast to 2028
DUBLIN, Oct. 1, 2019 /PRNewswire/ -- The "IgG4-Related Disease - Market Insights, Epidemiology, and Market Forecast to 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
IgG4-Related Disease-Market Insights, Epidemiology, and Market Forecast, 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of IgG4-Related Disease in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of IgG4-Related Disease from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
The IgG4-Related Disease market report gives the thorough understanding of the IgG4-Related Disease by including details, such as disease introduction, immunoglobulins, clinical manifestations, pathophysiological mechanisms, symptoms, clinical Features of Organ system involvement, pathophysiology, the pathogenesis of IgG4-related disease and diagnosis. It also provides treatment algorithms and treatment guidelines for IgG4-Related Disease in the US, Europe, and Japan.
IgG4-Related Disease Market Outlook
IgG4-related disease (IgG4-RD) is a systemic fibro inflammatory disease characterized by dense infiltration of IgG4-positive plasma cells in the affected tissue(s) with or without elevated plasma levels of IgG4. Some patients with asymptomatic IgG4-RD can be watched without treatment, e.g., asymptomatic lymphadenopathy or mild submandibular gland enlargement. Special attention should be made to active IgG4-RD in the pancreas, biliary tree, aorta, mediastinum, kidneys, retroperitoneum, and mesentery as in those cases starting therapy is urgent that must be considered.
IgG4-Related Disease Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allowing the comparison of the drugs on the basis of market share and size will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for IgG4-Related Disease such as XmAb5871 (Xencor) and Abatacept (Bristol-Myer Squibb) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the IgG4-Related Disease market.
Key Topics Covered:
1. Key Insights
2. IgG4-Related Disease Market Overview at a Glance
2.1. Market Share (%) Distribution of IgG4-Related Disease in 2017
2.2. Market Share (%) Distribution of IgG4-Related Disease in 2028
3. Disease Background and Overview: IgG4-Related Disease
3.1. Introduction
3.2. Immunoglobulins
3.3. Clinical Manifestations
3.4. Pathophysiological Mechanisms
3.5. Symptoms
3.6. Clinical Features of Organ System Involvement
3.7. Pathophysiology
3.8. Pathogenesis of IgG4-related disease
3.9. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM IgG4-Related Disease Total Patient Population
4.3. 7MM IgG4-Related Disease Total Diagnosed Patient Population
5. Country Wise-Epidemiology of IgG4-Related Disease
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. IgG4-Related Disease (IgG4-RD) Prevalent Population in the United States
5.1.3. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in the United States
5.1.4. IgG4-RD Gender-specific Prevalent Population in the United States
5.1.5. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States
5.2. EU5 Countries
5.3. Germany
5.4. France
5.5. Italy
5.6. Spain
5.7. United Kingdom
5.8. Japan
6. Treatment
6.1. Glucocorticoids
6.1.1. Induction Therapy
6.1.2. Maintenance therapy
6.2. Conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in IgG4-RD
6.2.1. B Cell-Targeted Therapy in IgG4-RD
6.2.2. Plasmablasts as a target of treatment
6.3. Glucocorticoids sparing agents
6.4. Alternative methods
6.5. Future Therapeutic Directions
6.5.1. CD4+ CTL-directed treatments
6.5.2. Anti-fibrosis Therapies
6.5.3. Recent Advancement
7. International Consensus Guidance Statement on the Management and Treatment of IgG4Related Diseases
7.1. Statement 1: Patient evaluation
7.1.1. Serologic testing
7.1.2. Other laboratory markers
7.1.3. Radiology
7.2. Statement 2: Tissue confirmation prior to treatment
7.3. Statement 3: Indications for therapy
7.3.1. Urgent treatment
7.3.2. Other triggers for therapy
7.3.3. Highly fibrotic lesions
7.4. Statement 4: Remission induction with glucocorticoids
7.5. Statement 5: The use of steroidsparing agents
7.5.1. Conventional steroidsparing medications
7.5.2. B cell depletion as a steroidsparing approach
7.6. Statement 6: The use of maintenance therapy following remission induction
7.7. Statement 7: Managing disease relapse
8. Unmet needs
9. Emerging Drugs
9.1. Key Cross Competition
9.2. Obexelimab (XmAb5871): Xencor
9.3. Abatacept: Bristol-Myer Squibb
10. IgG4-Related Disease: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of IgG4-Related Disease in the 7MM
11. The United States Market Outlook
11.1. United States Market Size
11.1.1. Total Market size of IgG4-Related Disease
11.1.2. Market Size by Therapies
12. EU-5 Countries: Market Outlook
13. Japan: Market Outlook
14. Market Drivers
15. Market Barriers
Companies Mentioned
- Xencor
- Bristol-Myer Squibb
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/y00o06
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article